5:53 PM
 | 
Oct 29, 2013
 |  BC Extra  |  Company News

Pfizer reports 3Q13 earnings, partners tanezumab with Lilly

Pfizer Inc. (NYSE:PFE) disclosed in its 3Q13 earnings on Tuesday that it partnered with Eli Lilly and Co. (NYSE:LLY) to jointly develop and commercialize worldwide Pfizer's tanezumab ( PF-4383119). The humanized mAb against nerve growth factor (NGF) has completed Phase II testing but is on a partial clinical hold....

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >